论文信息 - Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice

Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice

Dupilumab, an anti-IL-4ɑ monoclonal antibody, has shown a positive benefit-risk ratio when treating moderate to severe atopic dermatitis (AD) in clinical studies (1). High persistence on dupilumab has recently been reported in clinical-practice setting with 77% of patients remaining in treatment for 12 months in a retrospective study including 1,963 patients with AD but reasons for discontinuation were not investigated (2).

[1] J. Silverberg,et al. Real-world persistence with dupilumab among adults with atopic dermatitis. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[2] John D. Davis,et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study , 2020 .

[3] J. Giovannelli,et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. , 2019, Journal of the American Academy of Dermatology.

[4] M. Cork,et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) , 2018, The British journal of dermatology.

[5] G. Yancopoulos,et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.

[6] J. Silverberg,et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.